Filing Details

Accession Number:
0000899243-19-019495
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-11 20:31:06
Reporting Period:
2019-07-09
Accepted Time:
2019-07-11 20:31:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1685071 Dova Pharmaceuticals Inc. DOVA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164426 Joseph Edelman C/O Perceptive Advisors Llc
51 Astor Place, 10Th Floor
New York NY 10003
No No Yes No
1224962 Perceptive Advisors Llc 51 Astor Place, 10Th Floor
New York NY 10003
No No Yes No
1249675 Ltd Fund Master Sciences Life Perceptive C/O Perceptive Advisors Llc
51 Astor Place, 10Th Floor
New York NY 10003
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-07-09 29,834 $16.61 3,653,435 No 4 P Indirect See footnote
Common Stock Acquisiton 2019-07-10 12,354 $16.89 3,665,789 No 4 P Indirect See footnote
Common Stock Acquisiton 2019-07-11 42,916 $16.67 3,708,705 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The transaction was executed in multiple trades at prices ranging from $16.46 to $16.75. The price above reflects the weighted average price. Detailed information regarding the number of shares transacted at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
  2. The transaction was executed in multiple trades at prices ranging from $16.54 to $16.75. The price above reflects the weighted average price. Detailed information regarding the number of shares transacted at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
  3. The transaction was executed in multiple trades at prices ranging from $16.43 to $16.75. The price above reflects the weighted average price. Detailed information regarding the number of shares transacted at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
  4. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.